ARGENX SE (ARGX.BR) Stock Fundamental Analysis
EBR:ARGX - Euronext Brussels - NL0010832176 - Common Stock - Currency: EUR
We assign a fundamental rating of 5 out of 10 to ARGX. ARGX was compared to 71 industry peers in the Biotechnology industry. ARGX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ARGX is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
ARGX had positive earnings in the past year.
ARGX had negative earnings in 4 of the past 5 years.
ARGX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ARGX (17.37%) is better than 95.77% of its industry peers.
ARGX has a Return On Equity of 19.54%. This is amongst the best in the industry. ARGX outperforms 85.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.37% | ||
| ROE | 19.54% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ARGX has a Profit Margin of 38.03%. This is amongst the best in the industry. ARGX outperforms 97.18% of its industry peers.
ARGX has a better Gross Margin (89.62%) than 87.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 38.03% | ||
| GM | 89.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ARGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for ARGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ARGX has an Altman-Z score of 42.38. This indicates that ARGX is financially healthy and has little risk of bankruptcy at the moment.
ARGX's Altman-Z score of 42.38 is amongst the best of the industry. ARGX outperforms 100.00% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ARGX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.01, ARGX belongs to the top of the industry, outperforming 87.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 42.38 |
ROIC/WACCN/A
WACC7.57%
2.3 Liquidity
A Current Ratio of 8.53 indicates that ARGX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 8.53, ARGX belongs to the best of the industry, outperforming 92.96% of the companies in the same industry.
A Quick Ratio of 7.88 indicates that ARGX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 7.88, ARGX belongs to the best of the industry, outperforming 92.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.53 | ||
| Quick Ratio | 7.88 |
3. Growth
3.1 Past
ARGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 133.66%, which is quite impressive.
The Revenue has grown by 23.38% in the past year. This is a very strong growth!
The Revenue has been growing by 94.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)133.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%155.36%
Revenue 1Y (TTM)23.38%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%82.18%
3.2 Future
Based on estimates for the next years, ARGX will show a very strong growth in Earnings Per Share. The EPS will grow by 106.31% on average per year.
Based on estimates for the next years, ARGX will show a very strong growth in Revenue. The Revenue will grow by 31.13% on average per year.
EPS Next Y576.65%
EPS Next 2Y242.7%
EPS Next 3Y155.24%
EPS Next 5Y106.31%
Revenue Next Year60.95%
Revenue Next 2Y45.7%
Revenue Next 3Y36.94%
Revenue Next 5Y31.13%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ARGX is valuated quite expensively with a Price/Earnings ratio of 352.50.
Based on the Price/Earnings ratio, ARGX is valued a bit cheaper than the industry average as 78.87% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 28.79, ARGX is valued quite expensively.
ARGX is valuated quite expensively with a Price/Forward Earnings ratio of 52.07.
80.28% of the companies in the same industry are more expensive than ARGX, based on the Price/Forward Earnings ratio.
ARGX is valuated expensively when we compare the Price/Forward Earnings ratio to 21.38, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 352.5 | ||
| Fwd PE | 52.07 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ARGX's earnings are expected to grow with 155.24% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.61
PEG (5Y)N/A
EPS Next 2Y242.7%
EPS Next 3Y155.24%
5. Dividend
5.1 Amount
ARGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EBR:ARGX (4/25/2025, 7:00:00 PM)
535.8
+4.2 (+0.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners39.35%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap32.72B
Analysts84
Price Target705.22 (31.62%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7909.56%
Min EPS beat(2)-38.07%
Max EPS beat(2)15857.2%
EPS beat(4)2
Avg EPS beat(4)3984.41%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)2003.12%
EPS beat(12)8
Avg EPS beat(12)1344.81%
EPS beat(16)12
Avg EPS beat(16)1027.8%
Revenue beat(2)2
Avg Revenue beat(2)6.37%
Min Revenue beat(2)5.75%
Max Revenue beat(2)6.99%
Revenue beat(4)3
Avg Revenue beat(4)5.41%
Min Revenue beat(4)-0.25%
Max Revenue beat(4)9.17%
Revenue beat(8)7
Avg Revenue beat(8)7.53%
Revenue beat(12)11
Avg Revenue beat(12)27.61%
Revenue beat(16)14
Avg Revenue beat(16)43.67%
PT rev (1m)7.17%
PT rev (3m)17.99%
EPS NQ rev (1m)5.28%
EPS NQ rev (3m)37.7%
EPS NY rev (1m)10.25%
EPS NY rev (3m)81.3%
Revenue NQ rev (1m)0.94%
Revenue NQ rev (3m)7.74%
Revenue NY rev (1m)0%
Revenue NY rev (3m)8.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 352.5 | ||
| Fwd PE | 52.07 | ||
| P/S | 16.99 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.73 | ||
| P/tB | 9.03 | ||
| EV/EBITDA | N/A |
EPS(TTM)1.52
EY0.28%
EPS(NY)10.29
Fwd EY1.92%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS31.53
BVpS61.36
TBVpS59.32
PEG (NY)0.61
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.37% | ||
| ROE | 19.54% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 38.03% | ||
| GM | 89.62% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.53 | ||
| Quick Ratio | 7.88 | ||
| Altman-Z | 42.38 |
F-ScoreN/A
WACC7.57%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)133.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%155.36%
EPS Next Y576.65%
EPS Next 2Y242.7%
EPS Next 3Y155.24%
EPS Next 5Y106.31%
Revenue 1Y (TTM)23.38%
Revenue growth 3Y63.92%
Revenue growth 5Y94.61%
Sales Q2Q%82.18%
Revenue Next Year60.95%
Revenue Next 2Y45.7%
Revenue Next 3Y36.94%
Revenue Next 5Y31.13%
EBIT growth 1Y97.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year959.92%
EBIT Next 3Y190.57%
EBIT Next 5Y115.14%
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A